ADRIÁN GARCIA VILLA

Dr. ADRIÁN GARCIA VILLA

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2023 in Thrombosis Research
Verified
Journal Article
Closed access
AVADRIÁN GARCIA VILLA
ADRIÁN GARCIA VILLA
JCJuan José Criado-Álvarez
Juan José Criado-Álvarez
MCMaría Carnevali
María Carnevali
MAMario Aramberri
Mario Aramberri
CFCarme Font
Carme Font
CDCarmen Díaz-Pedroche
Carmen Díaz-Pedroche

2 March 2022 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
PVPaula Lucía Villalba-Cuesta
Paula Lucía Villalba-Cuesta
CÁCarmen Álvaro-Vegue
Carmen Álvaro-Vegue
CCCarlos Girado Carrasco-Muñoz
Carlos Girado Carrasco-Muñoz
CGCarmen Gomis-Goti
Carmen Gomis-Goti
AVADRIÁN GARCIA VILLA
ADRIÁN GARCIA VILLA
Introduction: Androgen deprivation therapy remains the essential treatment for disseminated prostate cancer. Interstitial pneumonitis following this therapy has been documented for just a few cases. However, reported cases frequently describe the onset of symptoms after recent administration (days or a few weeks) of both GnRH analogues and androgen antagonists, which makes the precise individual impact of each treatment difficult to estimate. Case report: This report presents a case of a 94-year-old patient with interstitial pneumonitis whose onset started three months after the first dose of leuprorelin and bicalutamide for a metastatic prostate cancer. Management and outcome: Once other possible diagnosis were ruled out, empiric corticosteroid treatment was initiated within 48 h of the admission. A spectacular clinical and radiological improvement was observed after 3 doses of steroids, enabling the patient to recover his basal respiratory situation. We considered that the most probable cause was toxic interstitial pneumonitis induced by leuprorelin. Discussion: To our knowledge, it describes the longest interval between last administration of antiandrogen therapy and the development of pneumonitis. This fact may support a direct relation with leuprorelin, whose serum levels remain high for months because of its long-acting depot formulation.

14 March 2024 in Journal of Thrombosis and Thrombolysis
Verified
Journal Article
Closed access
PDF file
MAMario Aramberri
Mario Aramberri
JGJesús González-Olmedo
Jesús González-Olmedo
AVADRIÁN GARCIA VILLA
ADRIÁN GARCIA VILLA
AVAne Villanueva
Ane Villanueva
CMCristina Castillo Maza
Cristina Castillo Maza
CDCarmen Diaz-Pedroche
Carmen Diaz-Pedroche

11 July 2022 in TH Open
Verified
Journal Article
Open access
PDF file
MAMario Aramberri
Mario Aramberri
MBMariana Benegas
Mariana Benegas
MSMarcelo Sanchez
Marcelo Sanchez
DMDiego Muñoz-Guglielmetti
Diego Muñoz-Guglielmetti
CZCarles Zamora
Carles Zamora
CFCarme Font
Carme Font
Background There is scarce information regarding the prevalence and clinical impact of saddle pulmonary embolism (PE) in patients with cancer. Objectives This study aimed to assess the prevalence, clinical findings, and short-term outcomes of patients with cancer-related saddle PE including acute symptomatic and unsuspected events. Patients/Methods Consecutive patients with cancer-related PE (March 1, 2006–October 31, 2014) were retrospectively reviewed by a chest radiologist to assess PE burden and signs of right ventricular (RV) overload. The clinical outcomes within 30 days were evaluated according to saddle versus nonsaddle PE. Results Thirty-six (12%) out of 289 patients with newly diagnosed cancer-related PE presented with saddle PE. Saddle PE was found in 21 cases (58%) with acute symptomatic PE and the remaining 15 cases (42%) were found as unsuspected findings. Patients with saddle PE had more frequently experienced a previous thrombotic event (31 vs. 13%; p = 0.008), and it occurred more frequently as an acute symptomatic event (58 vs. 39%; p = 0.025) compared with those with nonsaddle PE. Signs of RV overload including RV/left ventricle ratio ≥1 (22 vs. 4%; p < 0.001) and interventricular septum displacement (53 vs. 20%; p < 0.001) were also more common in patients with saddle PE compared with nonsaddle PE. Overall, PE-related mortality, venous thromboembolism recurrence, and major bleeding within 30 days were found to be similar according to saddle versus nonsaddle PE. Conclusion Saddle PE is not uncommon in patients with cancer-related PE including in those with unsuspected PE. Similar 30-day outcomes were found according to saddle versus nonsaddle PE in our cohort.

12 September 2022 in TH Open
Verified
Journal Article
Open access
MAMario Aramberri
Mario Aramberri
MBMariana Benegas
Mariana Benegas
MSMarcelo Sanchez
Marcelo Sanchez
DMDiego Muñoz-Guglielmetti
Diego Muñoz-Guglielmetti
CZCarles Zamora
Carles Zamora
CFCarme Font
Carme Font
Background There is scarce information regarding the prevalence and clinical impact of saddle pulmonary embolism (PE) in patients with cancer. Objectives This study aimed to assess the prevalence, clinical findings, and short-term outcomes of patients with cancer-related saddle PE including acute symptomatic and unsuspected events. Patients/Methods Consecutive patients with cancer-related PE (March 1, 2006–October 31, 2014) were retrospectively reviewed by a chest radiologist to assess PE burden and signs of right ventricular (RV) overload. The clinical outcomes within 30 days were evaluated according to saddle versus nonsaddle PE. Results Thirty-six (12%) out of 289 patients with newly diagnosed cancer-related PE presented with saddle PE. Saddle PE was found in 21 cases (58%) with acute symptomatic PE and the remaining 15 cases (42%) were found as unsuspected findings. Patients with saddle PE had more frequently experienced a previous thrombotic event (31 vs. 13%; p=0.008), and it occurred more frequently as an acute symptomatic event (58 vs. 39%; p=0.025) compared with those with nonsaddle PE. Signs of RV overload including RV/left ventricle ratio ≥1 (22 vs. 4%; p<0.001) and interventricular septum displacement (53 vs. 20%; p<0.001) were also more common in patients with saddle PE compared with nonsaddle PE. Overall, PE-related mortality, venous thromboembolism recurrence, and major bleeding within 30 days were found to be similar according to saddle versus nonsaddle PE. Conclusion Saddle PE is not uncommon in patients with cancer-related PE including in those with unsuspected PE. Similar 30-day outcomes were found according to saddle versus nonsaddle PE in our cohort.

20 April 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
FMFrancisco Javier Teigell Muñoz
Francisco Javier Teigell Muñoz
LRLAIA LLOBERA RIUS
LAIA LLOBERA RIUS
LOLaura Medina Ortega
Laura Medina Ortega
PGPablo Villacé Gallego
Pablo Villacé Gallego
JMJavier Marco-Hernández
Javier Marco-Hernández
AVADRIÁN GARCIA VILLA
ADRIÁN GARCIA VILLA
Background/Objectives: Malnutrition and nutritional vulnerability are common in patients with cancer and are associated with adverse clinical outcomes, particularly among hospitalised patients. However, data specifically describing nutritional risk in patients admitted to medical oncology departments remain limited. This study aimed to estimate the prevalence of nutritional risk at hospital admission and to evaluate factors associated with nutritional risk and its clinical consequences. Methods: The REGIO registry is a national multicentre prospective cohort including adult patients with solid tumours admitted to medical oncology departments in 17 Spanish hospitals between February 2024 and January 2025. Nutritional risk was assessed within the first working day of hospitalisation using the Malnutrition Screening Tool (MST), with a score ≥ 2 indicating nutritional risk. Multivariable logistic regression models were used to identify factors associated with nutritional risk and its association with prolonged hospital stay and mortality. Results: A total of 1229 patients were included (median age 67.8 years; 59% male; 64% metastatic disease). Nutritional risk was identified in 53% of patients. In multivariable analysis, poorer functional status, tumour progression, recent exposure to cytotoxic chemotherapy, and tumour types with higher nutritional impact were independently associated with nutritional risk. Patients at nutritional risk had longer hospital stays (median 10 vs. 7 days; p < 0.001), a higher likelihood of prolonged hospitalisation (adjusted OR 1.38), and increased mortality at 30 days (adjusted OR 1.63) and 60 days after discharge (adjusted OR 1.53). Conclusions: In this large multicentre cohort, nutritional risk was highly prevalent and independently associated with worse clinical outcomes, supporting the clinical relevance of systematic nutritional screening at hospital admission in patients with cancer.